tiprankstipranks
Trending News
More News >
CombiGene AB (DE:COJ0)
FRANKFURT:COJ0

CombiGene AB (COJ0) Price & Analysis

Compare
0 Followers

COJ0 Stock Chart & Stats


Financials

COJ0 FAQ

What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was €0.08 and its highest was €0.25 in the past 12 months.
    What is CombiGene AB’s market cap?
    CombiGene AB’s market cap is €4.43M.
      When is CombiGene AB’s upcoming earnings report date?
      CombiGene AB’s upcoming earnings report date is Aug 22, 2025 which is in 73 days.
        How were CombiGene AB’s earnings last quarter?
        Currently, no data Available
        Is CombiGene AB overvalued?
        According to Wall Street analysts CombiGene AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does CombiGene AB pay dividends?
          CombiGene AB pays a Notavailable dividend of €0.018 which represents an annual dividend yield of N/A. See more information on CombiGene AB dividends here
            What is CombiGene AB’s EPS estimate?
            CombiGene AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does CombiGene AB have?
            CombiGene AB has 19,801,197 shares outstanding.
              What happened to CombiGene AB’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of CombiGene AB?
              Currently, no hedge funds are holding shares in DE:COJ0

              Company Description

              CombiGene AB

              CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
              Similar Stocks
              Company
              Price & Change
              Follow
              OncoZenge AB
              Modus Therapeutics Holding AB
              ExpreS2ion Biotech Holding AB
              Spago Nanomedical AB
              Sprint Bioscience AB
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis